-
公开(公告)号：US20200254101A1
公开(公告)日：2020-08-13
申请号：US16649703
申请日：2018-09-19
Inventor： Ryohei HIROSE , Takaaki NAKAYA , Yoshito ITOH
Abstract: A two-component local injection solution for submucosal injection, comprising the following (i) and (ii): (i) a polysaccharide aqueous solution containing at least one member selected from the group consisting of sodium alginate, carrageenan, and gellan gum; and (ii) an aqueous salt solution containing at least one cation selected from the group consisting of sodium ions and calcium ions, wherein when the polysaccharide is sodium alginate, the cation comprises calcium ions.
-
公开(公告)号：US20200032183A1
公开(公告)日：2020-01-30
申请号：US16573126
申请日：2019-09-17
Inventor： Kentaro NAKAMURA , Rie HANDO , Satoshi GOJO , Daisuke KAMI
Abstract: An object of the present invention is to provide a method of manufacturing a large number of uniform cell structures for a short period of time. According to the present invention, provided is a method of manufacturing a cell structure, including: a step of adding a mixture of biocompatible macromolecular blocks, cells, and a liquid medium to a first culture container having a culture surface on which the plurality of recessed portions are formed and a side wall part standing on an outer periphery of the culture surface such that a liquid surface of the mixture is over the culture surface; a step of allowing a first culture container to stand and forming a cell structure in the recessed portion; and a step of stirring and culturing a content of the first culture container in a second culture container including stirring means.
-
公开(公告)号：US20190338306A1
公开(公告)日：2019-11-07
申请号：US16474416
申请日：2017-12-28
Inventor： Junko Wakao , Tsunao Kishida , Tatsuro Taijiri , Osam Mazda
Abstract: Provided is a method for inducing a skeletal muscle cell including a step of introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell of a mammal.
-
公开(公告)号：US20190178757A1
公开(公告)日：2019-06-13
申请号：US16310842
申请日：2017-10-05
Inventor： Kazuo Umihira , Keizou Ogino , Osamu Ukimura , Kazumi Kamoi
Abstract: A tissue dividing jig includes a tissue dividing base; and a cutting blade set provided with a cutting blade member and a guide portion, the tissue dividing base and the cutting blade set have a positioning mechanism that fixes their positions mutually, the cutting blade member is provided with a cutting blade extending in a longitudinal direction of the tissue placement portion, the guide portion guides the cutting blade member to move the cutting blade member to a fixed position on the tissue dividing base, and the cutting blade is disposed such that when the cutting blade set is disposed at a predetermined position on the tissue dividing base by the positioning mechanism and the cutting blade member is moved using the guide portion, the cutting blade divides the needle biopsy tissue on the tissue placement portion in the longitudinal direction.
-
公开(公告)号：US20190083543A1
公开(公告)日：2019-03-21
申请号：US16078002
申请日：2017-02-14
Inventor： Shigeru KINOSHITA , Junji HAMURO , Chie SOTOZONO , Mario UENO
Abstract: The present invention complete a technique of treating a corneal disorder or disease by infusion into an anterior chamber of human eyes. Specifically, the present invention based on the findings discovered that cultured human corneal endothelial cells are comprised of a plurality of subpopulations, most of them are not suitable for infusion into patients. The above-described subject was overcome by providing, as a medicament, functionally high grade quality of cells having the function of mature differentiated human corneal endothelial cells which is a specific subpopulation and characterized by their biochemical and functional phenotypes. The present invention provides such a functional mature differentiated corneal endothelial cells, medicament comprising the same, and manufacturing method, quality control and techniques related thereto.
-
Patent Agency Ranking
公开(公告)号：US20170319665A1
公开(公告)日：2017-11-09
申请号：US15523282
申请日：2015-10-30
Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION , THE DOSHISHA , SENJU PHARMACEUTICAL CO., LTD.
Inventor： Noriko KOIZUMI , Naoki OKUMURA , Shigeru KINOSHITA
IPC: A61K38/39 , A61K35/30 , A61K31/4409 , A61K45/00 , A61K9/00
CPC classification number: A61K38/39 , A61K9/0048 , A61K31/4409 , A61K35/30 , A61K45/00 , A61K45/06 , A61P27/02 , A61K2300/00
Abstract: The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (α4β1γ1), laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or fragments of these.
-
公开(公告)号：US20170252484A1
公开(公告)日：2017-09-07
申请号：US15509912
申请日：2015-09-11
Inventor： Yoshihiro SOWA , Tsunao KISHIDA , Osam MAZDA
CPC classification number: A61L27/383 , A61K35/12 , A61K35/30 , A61L27/00 , A61L27/3675 , A61L27/3895 , A61L27/54 , A61L2430/32 , A61P25/00 , C12N5/0622 , C12N5/10 , C12N15/09 , C12N2501/60 , C12N2506/09 , C12N2506/1384 , C12N2506/28
Abstract: The present invention addresses the problem of providing a method for obtaining Schwann cells directly (by direct reprogramming) without passing through pluripotent stem cells, such as ES cells or iPS cells. As a means for solving this problem, the present invention provides a method for preparing Schwann cells that includes a step of introducing into somatic cells of a mammal at least one gene selected from the group consisting of SOX10 genes and KROX20 genes, or an expression product thereof.
-
公开(公告)号：US20170202910A1
公开(公告)日：2017-07-20
申请号：US15443913
申请日：2017-02-27
Applicant: Kyoto Prefectural Public University Corporation , The Doshisha , Senju Pharmaceutical Co., Ltd.
Inventor： Takahiro Nakamura , Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita , Kana Tominaga , Satoshi Kawasaki
IPC: A61K38/17
CPC classification number: A61K38/1709 , A61K35/30 , A61K38/00 , A61K48/00 , C07K14/705 , C12N5/0621 , C12N2501/40 , C12N2501/415 , C12Q1/6881 , C12Q2600/158 , G01N33/56966 , G01N2333/726 , G01N2800/16
Abstract: The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.
-
公开(公告)号：US09616101B2
公开(公告)日：2017-04-11
申请号：US14413066
申请日：2013-07-03
Applicant: Kyoto Prefectural Public University Corporation , The Doshisha , Senju Pharmaceutical Co., Ltd.
Inventor： Takahiro Nakamura , Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita , Kana Tominaga , Satoshi Kawasaki
IPC: A61K38/00 , A61K38/22 , A61K39/00 , C07K14/47 , C07K14/785 , C07K14/005 , A61K38/17 , A61K48/00 , C07K14/705 , A61K35/30 , G01N33/569 , C12N5/079 , C12Q1/68
CPC classification number: A61K38/1709 , A61K35/30 , A61K38/00 , A61K48/00 , C07K14/705 , C12N5/0621 , C12N2501/40 , C12N2501/415 , C12Q1/6881 , C12Q2600/158 , G01N33/56966 , G01N2333/726 , G01N2800/16
Abstract: The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.
-
50.发明申请THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM 审中-公开与内膜内皮细胞死亡相关的疾病治疗药物公开(公告)号：US20160296505A1
公开(公告)日：2016-10-13
申请号：US15031183
申请日：2014-10-30
Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION , THE DOSHISHA , SENJU PHARMACEUTICAL CO., LTD.
Inventor： Noriko KOIZUMI , Naoki OKUMURA , Shigeru KINOSHITA
IPC: A61K31/4439 , A61K31/4709 , A61K39/395 , A61K9/00 , A61K31/444 , C07K16/22
CPC classification number: A61K31/4439 , A61K9/0048 , A61K31/437 , A61K31/444 , A61K31/4709 , A61K31/519 , A61K31/713 , A61K38/00 , A61K39/3955 , C07K16/22
Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.
Abstract translation: 本发明提供了与内质网（ER）应激相关的疾病，病症或病症的治疗药物或预防药物。 具体地说，本发明提供了一种治疗药物或预防药物，用于与角膜上皮细胞内内质网（ER）应激相关的疾病，病症或病症，含有TGFβ信号抑制剂的药物。 作为优选的TGFβ信号抑制剂，该药物含有4- [4-（1,3-苯并间二氧杂环戊烯-5-基）-5-（2-吡啶基）-1H-咪唑-2-基]苯甲酰胺。
-
-
-
-
-
-
-
-
-
Search Results
138
records
(took 0.038 seconds)
